Invivyd

Regulatory Risks And Competition Will Impede Gains But Yield Promise

AnalystLowTarget

Not Invested

Community Contributor

Published

22 Aug 25

AnalystLowTarget's Fair Value

US$1.00

76.0% overvalued

04 Sep

US$1.76

77.1%

23.9%

77.1%

23.9%

You can edit this narrative until Aug 22 10:37 PM. Then, changes will post as Updates.

Author's Valuation

US$176.0% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$1

76.0% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

42.79%

Biotech revenue growth rate

8.93%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.80%

Calculation

US$15.70m

Earnings '28

9.44x

PE Ratio '28

US$148.20m

Market Cap '28

US$148.20m

Market Cap '28

121.74m

No. shares '28

US$1.22

Share Price '28

US$1.22 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$1.00

Fair Value '25